Alloway J A, Moriarty M J, Hoogland Y T, Nashel D J
Rheumatology Section, Veterans Affairs Medical Center, Washington, DC 20422.
J Rheumatol. 1993 Jan;20(1):111-3.
Twenty-seven patients presenting within 5 days of the onset of crystalline proven acute gout were prospectively treated with either indomethacin 50 mg tid or triamcinolone acetonide 60 mg intramuscularly. Patients with contraindications to therapy with indomethacin received triamcinolone acetonide. They were followed for 30 days. Resolution of all symptoms occurred at an average of 8 days for the indomethacin patients and 7 days in the triamcinolone patients. No side effects or episodes of rebound gout attacks occurred with the triamcinolone acetonide therapy. It is as safe and effective as indomethacin in the treatment of acute gout, and is particularly useful in patients with contraindications to therapy with nonsteroidal antiinflammatory drugs.
27例在确诊为结晶性急性痛风发作5天内就诊的患者,被前瞻性地给予吲哚美辛50毫克每日三次口服治疗,或曲安奈德60毫克肌肉注射治疗。有吲哚美辛治疗禁忌证的患者接受曲安奈德治疗。对他们进行了30天的随访。吲哚美辛组患者所有症状平均在8天内缓解,曲安奈德组患者为7天。曲安奈德治疗未出现副作用或痛风反跳发作。在治疗急性痛风方面,它与吲哚美辛一样安全有效,对有非甾体抗炎药治疗禁忌证的患者尤其有用。